AstraZeneca Pharma India Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹4365.45
- Today's High:
- ₹4554.95
- Open Price:
- ₹4549.95
- 52W Low:
- ₹2926.6176
- 52W High:
- ₹4367.9502
- Prev. Close:
- ₹4518.45
- Volume:
- 17151
Company Statistics
- Market Cap.:
- ₹107.35 billion
- Book Value:
- 235.476
- Revenue TTM:
- ₹10.66 billion
- Operating Margin TTM:
- 17.72%
- Gross Profit TTM:
- ₹6.43 billion
- Profit Margin:
- 12.48%
- Return on Assets TTM:
- 10.11%
- Return on Equity TTM:
- 18.05%
Company Profile
AstraZeneca Pharma India Limited had its IPO on under the ticker symbol ASTRAZEN.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. AstraZeneca Pharma India Limited has a staff strength of 947 employees.
Stock update
Shares of AstraZeneca Pharma India Limited opened at ₹4549.95 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹4365.45 - ₹4554.95, and closed at ₹4480.2.
This is a -0.85% slip from the previous day's closing price.
A total volume of 17,151 shares were traded at the close of the day’s session.
In the last one week, shares of AstraZeneca Pharma India Limited have increased by +4.48%.
AstraZeneca Pharma India Limited's Key Ratios
AstraZeneca Pharma India Limited has a market cap of ₹107.35 billion, indicating a price to book ratio of 15.5412 and a price to sales ratio of 9.3798.
In the last 12-months AstraZeneca Pharma India Limited’s revenue was ₹10.66 billion with a gross profit of ₹6.43 billion and an EBITDA of ₹2.01 billion. The EBITDA ratio measures AstraZeneca Pharma India Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, AstraZeneca Pharma India Limited’s operating margin was 17.72% while its return on assets stood at 10.11% with a return of equity of 18.05%.
In Q2, AstraZeneca Pharma India Limited’s quarterly earnings growth was a positive 167.2% while revenue growth was a positive 27.2%.
AstraZeneca Pharma India Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 80.9129
- PEG
Its diluted EPS in the last 12-months stands at ₹53.07 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into AstraZeneca Pharma India Limited’s profitability.
AstraZeneca Pharma India Limited stock is trading at a EV to sales ratio of 8.8477 and a EV to EBITDA ratio of 56.4358. Its price to sales ratio in the trailing 12-months stood at 9.3798.
AstraZeneca Pharma India Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 122.83%.
Balance sheet and cash flow metrics
- Total Assets
- ₹9.85 billion
- Total Liabilities
- ₹3.84 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 122.83%
AstraZeneca Pharma India Limited ended 2024 with ₹9.85 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹9.85 billion while shareholder equity stood at ₹5.89 billion.
AstraZeneca Pharma India Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹3.84 billion in other current liabilities, 50000000.00 in common stock, ₹5.84 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹5.00 billion and cash and short-term investments were ₹5.11 billion. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.
AstraZeneca Pharma India Limited’s total current assets stands at ₹8.35 billion while long-term investments were ₹0 and short-term investments were ₹105.70 million. Its net receivables were ₹1.08 billion compared to accounts payable of ₹2.28 billion and inventory worth ₹1.90 billion.
In 2024, AstraZeneca Pharma India Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, AstraZeneca Pharma India Limited paid ₹1.23 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹4480.2
- 52-Week High
- ₹4367.9502
- 52-Week Low
- ₹2926.6176
- Analyst Target Price
- ₹
AstraZeneca Pharma India Limited stock is currently trading at ₹4480.2 per share. It touched a 52-week high of ₹4367.9502 and a 52-week low of ₹4367.9502. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹3975.7 and 200-day moving average was ₹3503.11 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 8339.2% of the company’s stock are held by insiders while 377.7% are held by institutions.
Frequently Asked Questions About AstraZeneca Pharma India Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brand names; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brand names. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.